Previous 10 | Next 10 |
MindMed Announces At-The-Market Offering Canada NewsWire NEW YORK , May 16, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health ...
Mind Medicine(MNMD) Q1 2022 Earnings Conference Call May16, 2022, 08:30AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli - Executive President Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Okunewitch - Maxim Elemer Pi...
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) announced Monday its financial results for the first quarter of 2022. MindMed is a New York-based psychedelic medicine biotechnology company that develops psychedelic-inspired drugs and therapies to combat addiction and mental illn...
Although MindMed's (NASDAQ:MNMD) Q1 2022 net loss widened 34% to ~18.5M compared to the prior-year period, that was still enough to beat on the bottom line. The psychedelic therapy-focused pharma did not record any revenue. R&D expenses rose 50% to $10.2M due to additional headcount and s...
Psychedelics are finally, carefully, hitting its stride this year. Even with a dour stock market beating it up, mid-year indicators of a jazzed-up emerging psychedelics industry that is finding its way are everywhere. As psychedelics news continues to grab headlines in mains...
Mind Medicine press release (NASDAQ:MNMD): Q1 GAAP EPS of -$0.04 beats by $0.01. "The outset of 2022 was marked by significant progress across all aspects of the company that propelled our business forward, as we continued to advance and de-risk our three lead product candidates: MM-120 for t...
MindMed Reports First Quarter 2022 Financial Results and Business Highlights Canada NewsWire - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal , MD as Chief Commercial Of...
Mind Medicine (NASDAQ:MNMD) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.05 Revenue estimate at $0. Recent Strong Sell rating on the stock with commentary that goes: 'Mind Medicine: It's Best To Stay Far Away From This...
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management Canada NewsWire - Webinar to feature presentations from Kelly E. Dunn , PhD, MBA, and Stuart Gitlow , MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT - ...
Mind Medicine (NASDAQ:MNMD) said a mid-stage study showed beneficial effects of LSD and potential to safely mitigate symptoms of anxiety disorders. The company said that Matthias Liechti and Friederike Holze, MindMed collaborators at University Hospital Basel (UHB), reported data fr...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...